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INTRODUCTION
Cockayne syndrome (CS) is a rare, autosomal-recessive disor-
der that was first described in 1936 by Edward Cockayne.1 Early 
descriptions of CS identified the cardinal clinical features of the 
disorder: microcephaly and growth failure. Other recognized 
features include hearing loss, cataracts, retinal dystrophy, and 
developmental delay. Dermal photosensitivity is often consid-
ered a key feature of the diagnosis, particularly after defects 
in transcription-coupled nucleotide excision repair (tc-NER) 
were identified in classically affected patients.2,3 However, the 
importance of this feature has long been questioned.4,5 Since 
then, and despite the discovery of the principal genes for CS 
(CSA/ERCC8, CSB/ERCC6), sensitivity of patient fibroblasts to 
ultraviolet (UV) C irradiation has been considered the diag-
nostic test of choice.6 Many case reports and series have been 
published over the years, including the landmark paper by 
Nance and Berry,7 which reviewed 140 cases from the litera-
ture. Although comprehensive, those authors noted that such 
review data may be subject to bias due to differences in report-
ing. Primary data have never been systematically collected from 
a large cohort of affected individuals, and no guidelines for 
care exist. This study aimed to provide a comprehensive clini-
cal description of CS and recommendations for care, to assist 
clinicians in diagnosis and management, and when counseling 
families.
METHODS
Ethical approval was granted by the National Research Ethics 
Service Committee North East—Newcastle and North Tyneside 
2. Individuals affected by CS were identified by an international 
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Purpose: Cockayne syndrome (CS) is a rare, autosomal- recessive 
disorder characterized by microcephaly, impaired postnatal 
growth, and premature pathological aging. It has historically 
been considered a DNA repair disorder; fibroblasts from classic 
patients often exhibit impaired transcription-coupled nucleotide 
excision repair. Previous studies have largely been restricted to 
case reports and small series, and no guidelines for care have been 
established.
Methods: One hundred two study participants were identified 
through a network of collaborating clinicians and the Amy and 
Friends CS support groups. Families with a diagnosis of CS could 
also self-recruit. Comprehensive clinical information for analysis was 
obtained directly from families and their clinicians.
Results and Conclusion:  We present the most complete evalua-
tion of Cockayne syndrome to date, including detailed information 
on the prevalence and onset of clinical features, achievement of neu-
rodevelopmental milestones, and patient management. We confirm 
that the most valuable prognostic factor in CS is the presence of early 
cataracts. Using this evidence, we have created simple guidelines for 
the care of individuals with CS. We aim to assist clinicians in the rec-
ognition, diagnosis, and management of this condition and to enable 
families to understand what problems they may encounter as CS pro-
gresses.
Genet Med advance online publication 23 July 2015
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network of collaborating clinicians and through the Amy and 
Friends CS support groups. In addition, families with a diag-
nosis of CS could self-recruit to the study. Informed consent 
was obtained for inclusion of all participants. Individuals 
were included in the analysis if they had a diagnosis of CS 
confirmed by molecular genetic testing or impaired recovery 
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of RNA synthesis in fibroblasts following UVC irradiation. A 
small number of patients also were included without such con-
firmation if they had a clear clinical diagnosis of CS. Separate 
written, informed consent was provided for the publication of 
images. Primary data on different aspects of CS were system-
atically collected from affected families and their clinicians, as 
detailed in the Results. Wherever possible, clinicians reviewed 
original case notes, laboratory reports, and specialist interpre-
tations for investigations such as imaging. All survival curves 
are Kaplan–Meier estimates; P values were obtained using 
Mantel–Haenszel tests against the hypothesis that there is no 
difference in survival between groups.
RESULTS
One hundred two patients from 81 families across 4 major ethnic 
groups were recruited to the study (Supplementary Figure S1A 
online), comprising 44 females and 58 males. The mean age 
of recruited individuals was 11.5 years (range: 3 months to 39 
years; Supplementary Figure S1B online). All were micro-
cephalic and had growth failure leading to a proportionate 
short stature. At the time of analysis, 28 individuals had died; 
the mean age at death was 8.4 years (range: 17 months to 30 
years; Supplementary Figure S1B online). Data on the preva-
lence of clinical features within our cohort are summarized in 
Figure  1a, together with detailed information on cumulative 
incidence (Figure  1b), manifestation, progression, and man-
agement of these features (Figure 1c). Genetic confirmation of 
CS was available in 40 pedigrees: CSB mutations were found in 
28 (70%), CSA mutations in 11 (27.5%), and XPD mutations in 
1 (2.5%). Numerators/denominators appear in the text where 
information does not relate to the entire cohort (e.g., when age 
at onset is required for the analysis). Recommendations for care 
based on our findings appear in Table 1.
Antenatal and birth history
Eighty-seven of the 102 patients in the cohort were evaluated 
antenatally using ultrasound. Abnormalities were detected on 
21 scans: prenatal growth restriction was noted in 15, with a 
female-to-male ratio of 2:1. While the birth weight of all males 
identified in this way fell between the 0.4th and 2nd centiles for 
gestational age, this was between the 2nd and the 91st centiles 
for all females. Enlarged cerebral ventricles were noted in four 
cases and microcephaly in two cases.
Information on mode of delivery was available for 90 births: 
27% were Caesarean delivery, 4% were assisted and 69% normal 
vaginal deliveries. Birth weights were almost entirely within the 
normal range (0.4th–99.6th centiles) and, based on available 
birth head circumference data, most individuals with CS were 
normocephalic (Supplementary Figure S1C,D online). Our 
data demonstrate that the first occurrence of CS in any family is 
extremely difficult to diagnose antenatally or at delivery.
Facial phenotype
Early in life, children with CS may look completely normal 
(Figure 2). The facial features of some children may be crowded, 
or the eyes may appear small. What is considered the typical 
facial appearance, with a loss of subcutaneous and orbital fat 
making the nose more prominent and giving the eyes a sunken 
appearance, only develops with time. However, the facial phe-
notype may be much more subtle. Some individuals develop 
a sunken-eyed appearance without loss of subcutaneous fat. 
In addition, children with CS may hold their upper limbs in a 
flexed position.
Cardinal features: growth failure and microcephaly
Postnatal growth failure and microcephaly in CS are well docu-
mented.7,8 In our cohort, growth parameters at birth were largely 
within the low normal range (median weight –0.76 ± 1.20 SD; 
occipital frontal circumference –1.17 ± 1.29 SD). Postnatally, 
individuals with CS develop microcephaly and small stat-
ure (median occipital frontal circumference –7.34 ± 2.96SD; 
height –6.62 ± 3.09 SD; weight –6.62 ± 4.79 SD; Figure 3a). It 
is worth noting how wide the variation, particularly in height 
and weight, can be. Weight may initially fall across the centiles 
but continue to skim the bottom of the normal range early in 
life, or may rarely be within the normal range (Supplementary 
Figure S1E online). In some cases weight decreases rapidly 
below the normal range (Supplementary Figure S1F online). 
Microcephaly in CS has been described as progressive. This is 
a misnomer, which is unhelpful in discussions with families. 
Head circumference, as with other parameters, may be within 
the normal range early in life, but growth velocity rapidly 
declines to growth arrest, often between 1 and 2 years of age 
(Supplementary Figure S1G online). Height and weight also 
are arrested, though this occurs slightly later.
Hearing and vision 
Hearing and visual problems are common in CS. It has been 
suggested that sensorineural deafness should be considered a 
feature of the disorder.9 Where detailed assessment of hearing 
loss was available, however, we found 44% (20/45) had conduc-
tive or mixed hearing loss. Whichever type of hearing loss is 
present, it is almost exclusively bilateral. This presents in 21% 
(14/68) of cases neonatally and in 84% by age 10 years. While 
most affected individuals wear hearing aids, several have suc-
cessfully received cochlear implants. This may be especially 
Figure 1  Clinical features in Cockayne syndrome (CS). (a) Clinical features in our cohort in order of decreasing frequency. The asterisk indicates that the 
denominator is dependent on an investigation being performed; for example, 71 patients had serum analysis of liver function. Our data are compared with 
those presented by Nance and Berry7 (the values shown are independent, not cumulative). The considerable differences reflect the fact that our data have 
been systematically collected from primary sources, whereas the review was largely based on published case reports. (b) Cumulative frequency of features, 
corrected for survival. (c) Detailed information on clinical features, ordered as in (a). Grey bars are descriptive, white bars illustrate clinical progression, and black 
bars indicate management. n, number of patients in each analysis. (d) Chart illustrating how participants reached their current diagnosis. For “biopsy only,” 
“biopsy and genetic,” and “genetic only,” this indicates that a confident clinical diagnosis was not given beforehand.
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useful in individuals unable to wear both hearing aids and 
glasses at the same time.
Cataracts and photophobia are equally common, occurring 
in 48.5% of our cohort. In most cases cataracts are bilateral, and 
86% (38/44) occur by age 4 years. The cause of photophobia in CS 
remains elusive, but parents should be aware that children with 
CS may require sunglasses or shade to minimize this. Retinal dys-
trophy has long been recognized as a feature,7 typically with salt-
and-pepper pigmentation; this is present in 43% of our cohort.
Musculoskeletal 
Weakness and joint contractures are major features of CS. The 
lower limbs are more often affected than the upper limbs, par-
ticularly by contractures (in 64%), which may make caring for 
a child with CS difficult (e.g., changing diapers). Although 26% 
(11/42) of contractures present neonatally, they may occur 
throughout life. Physiotherapy input is likely to be required, 
and orthoses (e.g., splints) may prove useful in managing con-
tractures. Weakness has been infrequently reported previously7 
but affects 79% of our cohort and is progressive in 49% (39/80) 
of those. Similarly, scoliosis affects 48% of study participants 
and is progressive in 49% (24/49) of those. Treatment with a 
brace was required in four cases; in one patient the severity of 
scoliosis was thought to warrant surgical intervention, but the 
associated risks outweighed this.
Gastrointestinal and nutritional
Feeding and nutritional status are significant concerns in CS. 
Forty-eight percent of our cohort experienced postnatal feeding 
difficulties, and 57% developed gastroesophageal reflux disease. 
This is managed effectively in most cases using proton pump 
inhibitors, either alone or in combination with a prokinetic agent 
or  H2-receptor antagonist. In some individuals fundoplication 
may be required. Often, before a diagnosis is made, the growth of 
Table 1 Recommendations for care
Recommended active follow-up/surveillance
Diagnosis First-line molecular testing of CSA and CSB
Molecular testing of ERCC5 if COFS phenotype and CSA/CSB are normal
Named clinical input (should be easily accessible) Coordinating clinician (pediatrics, genetics if adult)
Dietician (before supplementary feeding required)
Physiotherapist/occupational therapist
Annual surveillance Cataracts (annual/biannual until 4 years old)
Retinal evaluation (lifelong)
Hearing assessment
Review by named clinician, including:
  Blood pressure, serum U&Es if symptomatic
  Liver function tests
  Blood glucose (from 10 years old)
Review by physiotherapy
Management for: Consider:
  Hypertension   Amlodipine ± ACE inhibitor
  GERD   Proton pump inhibitor ± prokinetic agent
  Tremor   Co-careldopa
  Recurrent pneumonia   Referral for swallow assessment
  Low temperature/unexplained symptoms   Thyroid function tests
If unclear whether weight loss is due to inadequate intake or 
pathological subcutaneous fat loss
Titrate NG/PEG feeds against weight gain, avoiding rapid increases in volume
AVOID (may be fatal) Metronidazole (and related antibiotics)
Exercise extra vigilance Opioids (consider starting at 1/3 dose)
Sedatives
Routine investigations that are commonplace but not indicated 
without clinical symptoms
  CT/MRI of brain Typical findings are not pathognomic, prognostic, or clinically actionable
  Echocardiography Reported abnormal in only one asymptomatic individual (dilatation ascending aorta)
  Renal ultrasound Renal calculi only actionable finding to date
ACE, angiotensin-converting enzyme; COFS, cerebro-oculofacioskeletal; CT, computed tomography; GERD, gastroesophageal reflux disease; MRI, magnetic resonance 
imaging; NG, nasogastric; PEG, percutaneous gastrostomy; U&E, urea and electrolytes.
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children with CS falls across the centiles. This may give rise to con-
cerns that dietary intake is inadequate. The clinical status of the 
child with CS, rather than growth, should guide the clinician as 
to whether supplementary nasogastric or percutaneous gastros-
tomy feeding is required. Of patients who commenced nasogas-
tric feeds, 63% (15/24) transitioned to percutaneous gastrostomy 
Figure 2 Changing features in Cockayne syndrome (CS). (a–l) Study participants (ages shown). Some individuals look completely normal early in life, 
whereas others may have subtle clues to the diagnosis, including crowded facial features and small eyes. While loss of subcutaneous fat, with development of 
the classic CS appearance (a, b, j), is not a feature in all, a sunken appearance to the eyes often develops with a loss of orbital fat. Patients g and h are sister 
and brother. The girls appearing in j are identical twins. Older individuals with CS are shown in k. Note also the flexed upper limb posture sometimes seen in 
patients with CS (l).
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feeding, with a mean interval of 7 months. Further concerns 
arise in individuals who lose subcutaneous fat (56%). Feed vol-
umes may be increased to counter this. Subcutaneous fat loss is 
inexorable when present, however, and increased calorie intake 
does not seem to prevent this. In addition, at this stage in their 
condition, the stomachs of individuals with CS seem to be less 
able to accommodate increases in feed volume, which may cause 
vomiting. Again, clinicians should be guided by the clinical status 
of the patient. We suggest adopting a commonsense approach, 
trialing a modest increase in feeds while monitoring weight gain 
to establish whether existing intake is adequate. Subcutaneous fat 
loss may also lead to leakage of stomach contents around per-
cutaneous gastrostomy tubes, reducing intake and causing skin 
irritation. Because patients may be receiving almost continu-
ous feeds, this can be socially disabling as well as distressing for 
families. We advocate early management of such leakage because 
subcutaneous fat loss is unlikely to improve. Bowel disturbance 
is also common in CS and may manifest as constipation and/or 
loose stools. A number of children with loose stools have experi-
enced particular problems with difficult-to-manage diaper rash. 
It is important to address this early to prevent deterioration of 
skin integrity.
Figure 3 Growth and development in Cockayne syndrome (CS). (a) Growth parameters are in the low normal range at birth, but rapid reduction in 
growth velocity to growth arrest occurs postnatally (PN). Z-scores were calculated using the LMS method on 1990 British Growth Reference data. n, number of 
patients plotted.32 Mean values ± 1 SD are shown. (b) Developmental ranges in CS. Ages at which participants achieve developmental milestones are shown. 
n, number of patients for whom age at attainment was available.
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Liver 
Hepatic dysfunction in CS has been previously noted,10 and in 
some cases it has been associated with cholestasis. Deranged liver 
function tests were found in 63% of patients in our cohort who 
had been tested (n = 71). Typically, transaminases are mildly ele-
vated and may progressively increase. The underlying reason for 
this phenomenon is unclear. Annual serum liver function tests 
may be useful clinically, allowing differentiation between an 
increasing baseline and acute hepatic injury. We have reported 
elsewhere that metronidazole causes acute hepatic failure in CS, 
which may be fatal and should be avoided.11
Cardiovascular, respiratory, immunology
Cold extremities, representing poor peripheral circulation, are 
the most common non-cardinal feature of CS (88.4%). This may 
be developmental in origin; teratomas generated using induced 
pluripotent stem cells derived from CS fibroblasts have very 
poor vasculature.12 In keeping with this, venous access is often 
difficult to achieve in individuals with CS (reported in 70%), 
and repeated attempts are a frequent cause of distress for both 
patients and families. Venous access should ideally be under-
taken in patients with CS only by experienced staff. Thirty-eight 
of our participants had an echocardiogram. This was abnormal 
in only one case, showing cardiac failure. There have been two 
previous reports of cardiac abnormalities in CS: dilated cardio-
myopathy13 and dilation of the ascending aorta.14 Respiratory 
problems affected 20 patients; 15 developed respiratory infec-
tions, thought to be due to aspiration. Recurrent respiratory 
infections in individuals with CS should therefore trigger 
speech and language therapy referral for swallowing assess-
ment. Immune problems are not a feature of CS, and affected 
individuals do not experience any increased incidence of infec-
tions compared with the general population; routine immunol-
ogy input is therefore not required. Other respiratory problems 
in our cohort include restrictive lung disease and asthma.
Renal and blood pressure
To date, there have been few reports regarding renal mani-
festations in CS.  Thirty-seven individuals in our cohort had 
renal ultrasound; this was abnormal in four, including uni-
lateral hypoplastic (but functional) kidney, abnormal kidney 
shape, and renal calculi. A single patient developed nephrotic 
syndrome at 6 years. Sixty-seven participants had blood pres-
sure evaluation; 18% (n = 12) were hypertensive. We therefore 
recommend blood pressure evaluation annually and at each 
admission in CS. One patient was managed using a β-blocker 
alone. At least one patient was refractory to this therapy. Others 
were managed effectively using amlodipine, alone or in com-
bination with an angiotensin-converting enzyme inhibitor or 
angiotensin-II receptor antagonist.
Endocrine
Forty-seven of 102 participants had laboratory assessment of 
blood glucose, with investigation type being dependent on 
local practice. Of those, 13% (n  =  6) had abnormal glucose 
metabolism. This affects older patients with CS and can prog-
ress from impaired glucose tolerance to required administra-
tion of insulin. The earliest occurrence of diabetes requiring 
treatment occurred at age 16 years. Autoimmune investiga-
tions, when performed, were normal. Although it is unclear 
how many participants were tested, eight had hypothyroidism; 
whether this was present from birth is unknown.
Neurological
Abnormal brain imaging is a well-recognized feature of CS.7,8,15 
Computed tomography and/or magnetic resonance imaging 
had been performed for 85 individuals in our cohort; abnor-
malities were detected in 83.5% (71/85). Calcification was pres-
ent in 55% (47/85). This principally affects the basal ganglia, but 
diffuse cortical calcification may also be seen. This may repre-
sent more complex mineralization, rather than simple calcifica-
tion, since microscopic examination also reveals the coincident 
presence of iron.16 White matter changes (38%, 33/85) comprise 
dysmyelination or hypomyelination. Cerebellar hypoplasia or 
atrophy, enlarged cerebral ventricles, and thinning of the cor-
pus callosum may also be seen. While calcification of the basal 
ganglia may point toward this diagnosis, the intracranial find-
ings in CS are not pathognomonic, prognostic, or clinically 
actionable, and imaging may therefore be of limited value to 
the patient.
Seizure disorders and tremor have been infrequently 
reported previously,7 but they affect 23 and 66% of our cohort, 
respectively. In the majority of affected patients seizures are 
ongoing, and there is no predominant seizure type. Tremor 
among our patients is most often an intention tremor; in some 
cases onset is associated with apparent developmental regres-
sion, as children become less skilled in fine and gross motor 
domains. Despite a previous report showing a good response to 
 carbidopa-levodopa in individuals with CS with tremor,17 very 
few participants received any treatment for this. Progressive 
neurodegeneration also has been described as a prominent fea-
ture in CS. We are not yet able to provide a detailed assessment 
of this in our cohort.
Neurodevelopment
Developmental delay is frequently reported in CS, although what 
families and clinicians might expect to observe is unknown. We 
therefore collected data on the age at which our cohort reached 
easily recognized developmental milestones (Figure 3b). Early 
development in particular may seem normal. Please note that 
these data represent only those individuals reaching each mile-
stone, when the age at attainment was also known; some chil-
dren with CS never develop the ability to roll over.
Dermatological and dental 
In three individuals the presence of photosensitivity was 
unclear because of preemptive management. Twenty-three of 
99 study participants have no dermal photosensitivity. Forty-six 
of 99 sunburn easily, but more explicit photosensitivity is pres-
ent in only 40; these participants sunburn on cloudy days or 
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blister following exposure to sunlight. Sun avoidance prevents 
issues among the latter group, whereas the former group effec-
tively use simple measures, such as the use of sunscreen and 
hats. Individuals with CS are not at increased risk of developing 
skin cancers. Thinning hair and skin hyperpigmentation have 
been noted in previous reports and are present in 46 and 29% of 
our cohort, respectively, but they have no clinical significance. 
There is no evidence to support routine dermatology input in 
CS. Review may be required upon the initial presentation of 
more marked photosensitivity, however, and may be useful in 
individuals with dry or itchy skin. Dental caries, which likely 
represents enamel hypoplasia,9 has been reported more fre-
quently in the literature than they occur in our cohort (46.4%).7 
Nevertheless, families should be encouraged to maintain regu-
lar dental review so that problems relating to enamel hypoplasia 
can be addressed early.
Medication
We already highlighted (above and elsewhere) that metronida-
zole causes acute hepatic failure in CS, which may be fatal. The 
clinical presentation can be similar to an untreated paracetamol 
overdose, with extremely increased transaminase concentra-
tions and significant clotting abnormalities. Metronidazole is 
therefore absolutely contraindicated in CS. Antibiotics of the 
same class should also be avoided, or used with extreme cau-
tion and close monitoring of liver function. There is no evi-
dence of toxicity associated with drugs metabolized in the liver 
in general.
An exaggerated response to sedative and opioid medica-
tions—from respiratory depression to blunted affect lasting sev-
eral days following administration of codeine—was reported in 
five cases.
DISCUSSION
CS is a rare condition that may be extremely difficult to rec-
ognize early in life. It has historically been considered a DNA 
repair disorder, yet the only feature that can be confidently 
attributed to defective tc-NER is photosensitivity. This prob-
lem has been highlighted by the identification of patients with 
UV-sensitive syndrome caused by mutations in CSA or CSB.18,19 
These patients have a DNA repair defect identical to that in 
those with CS, but they have normal growth and development 
and lack microcephaly or features of premature pathological 
aging. A defect in transcription, independent of tc-NER, has 
been suggested as the cause of CS-specific pathology20 but simi-
larly suffers from the reports of patients with CSA/CSB muta-
tions with UV-sensitive syndrome and cannot explain why the 
particular features seen in CS occur together. Various additional 
roles for CSB have been tentatively suggested: in modulating 
the activity of base excision repair enzymes,21 in stabilizing 
mitochondrial DNA repair,22,23 in hindering the repair of cova-
lent DNA–DNA topoisomerase I complexes,24 and in maintain-
ing telomere stability.25 A role for the CSB-PGBD3 piggyBAC 
fusion protein has also been suggested; this protein is pur-
ported to regulate gene expression through interaction with 
chromosomal activator protein-1 proteins at tumor-promoting 
antigen response element motifs.26 However, there is no evi-
dence that any of the additional processes in which CSB may 
be involved are significant in producing the CS phenotype, and 
no link between CSA and these processes has been identified. 
Any unifying pathogenic mechanism underlying the clinical 
features in CS is currently unknown, despite the detailed char-
acterization of tc-NER.
Incidence
The incidence of CS in Western Europe is estimated at 2.7 per 
million live births.27 This may be an underestimate due to dif-
ficulties in reaching a diagnosis, in particular the reliance on 
dermal photosensitivity as a diagnostic feature. There are also 
examples of very high carrier frequency (1:15) in genetically 
isolated communities in Israel.28,29
Diagnosis
Modified criteria for the diagnosis of CS have recently been 
suggested (Supplementary Figure S2A online). Growth fail-
ure, microcephaly, and developmental delay were considered 
mandatory. However, our data suggest that developmental 
delay may be a poor discriminating factor for early diagnosis, 
since development may initially be within normal limits. We 
evaluated how effective the suggested minor criteria would have 
been in reaching a diagnosis of CS in our cohort. To do this, we 
used caries as a proxy for enamel hypoplasia and assumed that 
all patients had evidence of enophthalmos at diagnosis (since 
we had no objective evidence on this). Using these criteria, 
36% of our cohort would have been diagnosed as having CS 
(Supplementary Figure S2B online), and only 20% would be 
diagnosed if milder presentations of photosensitivity were not 
recognized. The ineffectiveness of these criteria reflect the vari-
ability in phenotype between patients with CS, which should be 
taken into account during clinical evaluation.
We suggest that CS should be suspected in any child with 
postnatal growth failure, microcephaly, and any two of the fol-
lowing: persistently cold hands and feet, bilateral hearing loss, 
dermal photosensitivity, (intention) tremor, joint contractures, 
progressive loss of body fat, cataracts, or typical facial features. 
Using these criteria increases clinical recognition of CS in our 
cohort to around 90%.
Establishing an unequivocal diagnosis in CS is important (i) 
for proper management of the patient, (ii) to empower fami-
lies in caring for affected individuals, and (iii) to provide accu-
rate genetic counseling to parents and siblings. Historically, 
the ability of patient fibroblasts to resume RNA synthesis fol-
lowing UVC-induced DNA damage has been the mainstay of 
diagnosis in CS. However, this requires a skin biopsy, may pro-
duce equivocal results, and does not furnish the clinician with 
optimal information for genetic counseling. Furthermore, in 
our experience, if a clear tc-NER defect is present, a molecular 
genetic diagnosis can be achieved, suggesting that skin biopsy 
is usually unnecessary. DNA sequencing may also resolve the 
diagnosis in cases with equivocal tc-NER results. Therefore, we 
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Figure 4 Prognostic factors in Cockayne syndrome (CS). The occurrence of cataracts before 3 years of age is the single most valuable prognostic factor in CS 
(a), having statistically extremely significant associations with reduced survival and shorter intervals to development of several other clinical features associated with 
reduced quality of life. Severe photosensitivity is associated with earlier onset of contractures, but not other factors affecting quality of life, or mortality (b). Having 
mutations in CSB (rather than CSA) has a borderline significant association with reduced survival only (c). For all plots, Kaplan–Meier estimates of the survival curve 
and 95% confidence intervals are shown. Statistical tests are Mantel–Haenszel tests of difference in the survival curve between groups.
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have adopted first-line molecular genetic testing of CSA and 
CSB in suspected cases of CS, which avoids the uncertainty of 
equivocal biopsy results, provides clear recurrence information 
for parents, and allows definitive prenatal testing and testing 
for potential carriers and their partners, if this is desired. We 
have successfully diagnosed patients using DNA extracted from 
blood, mouthwash, and dried bloodspot samples, avoiding the 
need for skin biopsy.
Classification and prognosis
Since Nance and Berry7 published their extensive review of the 
CS literature, clinicians have attempted to partition affected 
individuals into clinical subtypes. This is often confusing for 
families. In reality there is a clinical spectrum for each feature 
of CS, and affected individuals occupy a unique position on 
each. Phenotypic discordance between siblings is not unusual 
in our cohort. The only identified association with younger age 
at death in CS is early onset of cataracts (<3 years old).7 We 
reevaluated this in our cohort, confirming that this association 
is statistically extremely significant (P = 1.36 × 10−6); at 5 years, 
survival is ~60% for those patients with early cataracts and 95% 
for those without (Figure 4a). We also found significant asso-
ciations between early cataracts and the time to development of 
hearing loss (P = 4.43 × 10−7) and contractures (P = 0.028), but 
not tremor (P = 0.86) or loss of subcutaneous fat (P = 0.073). 
Degree of photosensitivity (Figure  4b) is not associated 
with survival (P  =  0.23), or time until the onset of tremor 
(P  =  0.398), though severe photosensitivity may be weakly 
associated with onset of hearing loss (P = 0.050); this feature is 
therefore a poor indicator of prognosis. However, severe pho-
tosensitivity does have a significant association with time until 
the onset of contractures (P = 8.31 × 10−5). We also evaluated 
the effect of genetic etiology on prognosis (Figure 4c). Having 
a CSB mutation has a borderline significant association with 
shorter survival (P = 0.045), but not with time until the onset 
of tremor (P = 0.078), hearing loss (P = 0.10), or contractures 
(P = 0.53). To prevent unnecessary confusion for families, we 
recommend that attempts at classification are avoided; instead, 
more descriptive information on mortality and morbidity in CS 
should be provided, based on the patient’s clinical presentation.
Similarly, cerebro-oculofacioskeletal syndrome has been 
separated from CS using the following diagnostic criteria: 
arthrogryposis, congenital microcephaly, cataracts/microph-
thalmia, and severe developmental delay and growth failure.30 
In essence, the main differentiating factor is the age at onset. 
For the purposes of management, cerebro-oculofacioskeletal 
may be considered part of the CS continuum. In such patients 
lacking CSA/CSB mutations, XPG (ERCC5) sequencing should 
be undertaken.31
Management
Each individual with CS should have a named, accessible cli-
nician who is responsible for coordinating their ongoing care. 
Because survival beyond childhood is unusual, a pediatrician 
often is most appropriate. Continued involvement of a clinical 
geneticist is not essential but may be useful, particularly for 
coordinating care in adults with CS. As with other pediatric 
disorders, transition to adult services is problematic, not least 
because adults with CS are small, and many adult services are 
ill-equipped to manage patients of this stature. If this is the 
case, continued access to pediatric services should be negoti-
ated locally if possible.
There is currently no cure for CS. The goal of surveillance in 
this condition is to maximize quality of life. Based on our find-
ings, we have developed a schedule for surveillance (Table 1). 
Many individuals with CS remain generally well and require 
nonelective hospital admission only late in their disease. It is 
important that they become known to local clinical services 
prior to this, and care should be managed locally wherever pos-
sible. Clinicians seeking further information or advice on CS 
are welcome to contact the study team (cockayne.syndrome@
nhs.uk) and to consider recruiting their patients to this ongo-
ing study.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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